In it, the authors discuss the role that real-time data can play in autologous cell therapy manufacturing. They note that access to real-time data has already benefitted several industries and believe that the same could be true for that of cell therapy manufacturing.

“Several examples have illustrated that this value can be significant,” they write. “Moving toward a more flexible and adaptive manufacturing processes for autologous cell therapies would require changes to the current regulatory structure but could potentially help the industry improve clinical outcomes and manage costs.”

Read the full article at https://doi.org/10.1016/j.cobme.2022.100389.